Review article: epidemiology and quality of life in functional gastrointestinal disorders (Q35936950)

11 August 2017

1 reference

title

Review article: epidemiology and quality of life in functional gastrointestinal disorders (English)

1 reference

11 August 2017

1 reference

1 reference

Chang L

1

1 reference

PubMed ID

15521853

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Alimentary Pharmacology & Therapeutics

11 August 2017

1 reference

11 August 2017

20 Suppl 7

1 reference

11 August 2017

31-39

1 reference

Systematic approach toward the clinical diagnosis of functional dyspepsia

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Costs of care for irritable bowel syndrome patients in a health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

The impact of functional gastrointestinal disorders on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Dyspepsia in general practice in Denmark. A 1-year analysis of consulters in general practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Long-term improvement in functional dyspepsia using hypnotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

AGA technical review on irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

Quality of life in functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02183.X

10.1111/J.1365-2036.2004.02183.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15521853